The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis
Launched by ZHENG LIU ENT · Apr 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying chronic rhinitis, a condition that affects a significant number of people in China—over 300 million. Chronic rhinitis can cause issues with breathing and even affect mental health, and many patients still struggle to find effective treatments. The researchers want to gather more information about this condition by surveying 30,000 patients across the country. They will collect details about symptoms, medical history, and biological samples to better understand what causes chronic rhinitis, why some patients do not respond well to treatment, and how to improve care for those affected.
To participate in the study, individuals must be Chinese, aged between 18 and 70, and have lived in the survey area for at least six months in the past year. Certain individuals, such as those with recent nasal surgery or severe mental health issues, will not be eligible to participate. If you join the study, you can expect to fill out questionnaires and undergo nasal examinations. This research aims to create a national database that will help develop better diagnostic tools and personalized treatment options for chronic rhinitis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chinese aged between 18 and 70 years old who have resided at the survey site for more than 6 months within the 12 months preceding the survey.
- Exclusion Criteria:
- • Exclusion criteria for questionnaire recipients: ① residents in specialized facilities (e.g., workshops, military barracks, student dormitories, nursing homes); individuals with mental or cognitive disorders (including dementia, aphasia, deafness); Exclusion criteria for nasal examination participants: ① individuals who have undergone sinus or nasal surgery, or diagnosed with sinusitis, nasal polyps, or nasal/nasopharyngeal tumors in the past year; ② patients with cystic fibrosis or primary ciliary dyskinesia; ③ residents in specialized facilities (e.g., workshops, military barracks, student dormitories, nursing homes); individuals with mental or cognitive disorders (including dementia, aphasia, deafness); (5) individuals currently under treatment for newly diagnosed tumors; ⑥ volunteers deemed unsuitable for the study by the research team.
About Zheng Liu Ent
Zheng Liu Enterprises is a dynamic clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization specializes in the design, management, and execution of clinical trials across various therapeutic areas. Leveraging a team of experienced professionals and a robust network of clinical sites, Zheng Liu Enterprises is committed to ensuring compliance with regulatory standards while fostering collaboration among stakeholders. Their mission is to facilitate the development of safe and effective treatments, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Zheng Liu
Principal Investigator
Tongji Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported